Skip to content

Clinical evaluation of antigen-specific chemokines CXCL9 in the diagnosis of tuberculosis infection

Clinical evaluation of antigen-specific chemokines CXCL9 in the diagnosis of tuberculosis infection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082055
Enrollment
Unknown
Registered
2024-03-19
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberculosis infection

Interventions

Sponsors

Beijing Chest Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Three groups of subjects were included in this study, including TB infected patients (TB patients and latent tuberculosis), non-TB patients and healthy controls. For TB patients, the confirmed cases and clinically diagnosed cases of TB in the "Diagnosis of Tuberculosis" standard (WS288-2017) are used as the gold standard for TB diagnosis; Non-TB patients are those clinically diagnosed with respiratory diseases such as pneumonia, lung cancer, bronchitis, bronchiectasis, non-tuberculous mycobacterium lung disease, and chronic obstructive emphysema, excluding TB patients; Latent TB, adult, without a known history of TB, who had normal chest radiography without clinical features such as fever, cough, night sweats, and weight loss, were confirmed to have negative results on the IGRA test. Healthy controls, adult, without a known history of exposure to MTB, who had normal chest radiography without clinical features, were confirmed to have negative results on the IGRA test.

Exclusion criteria

Exclusion criteria: Exclusion criteria ? Pregnant or lactating patients; ? Patients with hematological malignancy; ? HIV-infected persons; ? Combined with autoimmune diseases; ? Use immunosuppressants (including steroid hormones, mycophenolate, cyclophosphamide, rapamycin, cyclosporine, azathioprine, TNF antagonists, methotrexate, tacrolimus, etc.); ? After organ transplantation or hematopoietic stem cell transplantation.

Design outcomes

Primary

MeasureTime frame
chemokine CXCL9;Sensitivity;Specificity;Accuracy;

Countries

China

Contacts

Public ContactYu Pang

Beijing Chest Hospital Affiliated to Capital Medical University

pangyupound@163.com+86 138 1009 8209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026